Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide-2,3,3-d3, monohydrochloride
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C10H12D3N3O5 / HCl
Formula Weight: 296.72214
Notes: Benserazide-d3 is intended for use as an internal standard for the quantification of benserazide (Item No. 20298) by GC- or LC-MS. Benserazide is a peripherally restricted inhibitor of aromatic L-amino acid decarboxylase (AADC; IC50 = 0.53 µM).{46663} It also inhibits tryptophan oxygenase and kynureninase (Kis = 41.8 and 26.4 µM, respectively, in rat liver homogenates), as well as hexokinase 2 (HK2), HK1, and HK4 (IC50s = 5.5, 25.1, and 40.5 µM, respectively, for the recombinant human enzymes).{46664,46665} Benserazide (50-400 µM) is cytotoxic to SW480 colorectal cancer cells, an effect that can be reversed by HK2 siRNA knockdown, and inhibits proliferation of SW480, LoVo, HCT116, MCF-7, and SMMC-7721 cancer cells with IC50 values of 143, 151, 181.4, 186, and 210.4 nM, respectively.{46665} It reduces tumor growth in an SW480 mouse xenograft model when administered at doses of 300 and 600 mg/kg per day for 16 days. Benserazide (10 and 50 mg/kg) inhibits striatal AADC and enhances L-DOPA-induced increases in striatal dopamine levels in a mouse model of Parkinson's disease induced by 6-OHDA (Item No. 25330).{32006}
Deutsch
English
